N@N

Down More Than 20% From Its High, Is Now the Time to Buy Eli Lilly Stock?

The article from The Globe and Mail discusses the investment potential of Eli Lilly and Company (LLY) stock, which has experienced a significant decline of over 20% from its peak. Despite this drop, the article suggests that now might be an opportune time to invest in Eli Lilly due to several positive factors. These include the company's robust pipeline of new drugs, particularly in high-demand areas like diabetes and oncology, with notable mentions of drugs like Mounjaro for diabetes and potential treatments for Alzheimer's. Additionally, Eli Lilly's financial health remains strong with consistent revenue growth and a promising outlook for future earnings. The article also highlights the company's strategic moves, such as acquisitions and partnerships, which could bolster its market position. However, it also notes potential risks like patent expirations and competition from other pharmaceutical giants. Overall, the piece frames Eli Lilly as a potentially undervalued stock with significant growth prospects, appealing to investors looking for long-term gains in the healthcare sector.

Read the Full The Globe and Mail Article at [ https://www.theglobeandmail.com/investing/markets/stocks/LLY/pressreleases/29807676/down-more-than-20-from-its-high-is-now-the-time-to-buy-eli-lilly-stock/ ]